Recursion Pharmaceuticals...

NASDAQ: RXRX · Real-Time Price · USD
5.70
0.06 (1.06%)
At close: Aug 15, 2025, 12:34 PM

Recursion Pharmaceuticals Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-463.66M -328.07M -239.48M -186.48M
Depreciation & Amortization
36.49M 24.4M 11.76M 8.4M
Stock-Based Compensation
81.69M 53.5M 27.91M 14.84M
Other Working Capital
-38.37M -49.27M 103.15M -10M
Other Non-Cash Items
-13.7M 12.64M 11.37M 4.1M
Deferred Income Tax
n/a n/a n/a 827K
Change in Working Capital
n/a -50.26M 104.92M -306K
Operating Cash Flow
-359.17M -287.78M -83.52M -158.61M
Capital Expenditures
-13.7M -11.96M -37.36M -39.8M
Cash Acquisitions
277.1M 1.84M n/a 231.95M
Purchase of Investments
n/a n/a n/a -301.14M
Sales Maturities Of Investments
n/a 480K 230.61M 69.19M
Other Investing Acitivies
-3.35M -597K 230.31M -231.95M
Investing Cash Flow
260.06M -10.23M 193.25M -271.74M
Debt Repayment
-4.44M -766K -90K -12.8M
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
8.14M 12.81M 10.72M 8.44M
Financial Cash Flow
304.12M 140.13M 154.34M 458.54M
Net Cash Flow
201.6M -157.69M 263.76M 28.18M
Free Cash Flow
-372.87M -300.33M -120.88M -198.41M